The use of tienilic acid in nephrotic syndrome: a clinical study.
The diuretic and uricosuric activities of tienilic acid 250--50 mg daily over a minimum six week period have been studied in seven patients with the nephrotic syndrome secondary to glomerulonephritis proven by renal biopsy. Tienilic acid failed to control oedema in one patient who had to be withdrawn. In the six other patients a hypouricaemic effect with increased urate clearance was noted. No consistent effects were noted with respect to the serum cholesterol and triglyceride concentrations. No side effects were observed. It is concluded that in nephrotic patients tienilic acid behaves as a mild diuretic with consistent hypouricaemic and uricosuric effects.
D000293:Adolescent; D000328:Adult; D000368:Aged; D002784:Cholesterol / Q000097:blood; D005260:Female; D005665:Furosemide / Q000627:therapeutic use; D006016:Glycolates / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D008875:Middle Aged; D009404:Nephrotic Syndrome / Q000097:blood / Q000188:drug therapy* / Q000378:metabolism; D013148:Spironolactone / Q000627:therapeutic use; D013989:Ticrynafen / Q000627:therapeutic use*; D014280:Triglycerides / Q000097:blood; D014527:Uric Acid / Q000097:blood / Q000378:metabolism
D006016:Glycolates; D014280:Triglycerides; D014527:Uric Acid; D013148:Spironolactone; D005665:Furosemide; D002784:Cholesterol; D013989:Ticrynafen